
Gossamer’s Faheem Hasnain defends a round of positive PAH data as a clear win. But can these PhII results stand up to scrutiny?
Gossamer Bio $GOSS posted a statistically significant improvement for its primary endpoint in the key Phase II TORREY trial for lead drug seralutinib on Tuesday morning. But CEO Faheem Hasnain has some explaining to do on the important secondary of the crucial six-minute walk distance test — which will be the primary endpoint in Phase III — as the data on both endpoints fell short of expectations, missing one analyst’s bar on even modest success.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.